Provider review
Mochi Health Review: Care and Drug Evidence
Mochi separates membership from medication and now publishes dose-dependent compounded pricing. That improves comparison, provided the reader keeps the care subscription, pharmacy choice and clinical evidence distinct.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Mochi HealthOf Mochi Health’s 1 dated product claim documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Mochi is worth comparing if you want ongoing clinician access and are willing to check the combined care and medication quote. Its current pricing explanation is useful; a low starting medication price should not drive the clinical choice.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Mochi Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — The September 2026 pricing update lists representative semaglutide medication prices of $60–$99 per month, depending on dose, state and pharmacy. Membership is separate; obtain the account-specific full quote.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Mochi Health's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Mochi Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“A compounded, once-weekly subcutaneous semaglutide injection, prescribed at provider discretion.”
Read on the Mochi Health site, October 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry read October 13, 2026. This study supports the molecule and studied injection, not this provider’s compounded formulation.
This accurately identifies the route and prescription status without promising a specific weight-loss result. Semaglutide has trial evidence; the compounded product itself is not the finished intervention tested in STEP 1.2
Dispensing chain
Who actually fills your prescription
Read the full account
Mochi describes choosing among pharmacy partners and its published compounding discussion describes 503A pharmacies. Aequita appears in a historical quality-report statement, not a confirmation that it currently fills a particular order. Confirm the selected pharmacy directly.
Read on the Mochi Health site, October 2026.
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described program, not a document.
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Mochi publishes a page linking Aequita batch reports and explaining report types. The linked individual reports were not assessed here, and the page does not establish the testing or identity of a future dispensing pharmacy.
Read on the Mochi Health site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
Confirm treatment availability for your state
Read the full licensing claim
A public treatment listing does not establish eligibility for every state or every patient. Confirm the clinician and dispensing pharmacy for your location.
Read on the Mochi Health site, October 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- The product page distinguishes the medication charge from membership.
- The pricing update explains dose- and pharmacy-dependent variation.
- Public information provides a route to ask about pharmacy selection and reports.
- The lowest medication figure is not a complete monthly care cost.
- A historical pharmacy report does not verify a future prescription.
- Compounded and branded formulations require separate evidence assessment.
Verdict
The bottom line
Confirm the membership, selected medication and pharmacy together. Then assess whether the proposed prescription has evidence appropriate to your health goal.
Opens Mochi Health's website. A link is not a recommendation to take anything.
Separate the service from the prescription
Mochi’s semaglutide page identifies a compounded injection and states that the medication charge is additional to membership. It describes a video consultation and ongoing care access. Those are distinct things to evaluate: the quality and accessibility of the clinical relationship, the medication proposed, and the total cost of both. 1
A useful first conversation should establish who will review progress, how to get help between appointments and how treatment changes are handled. Availability of appointments matters, but it does not by itself establish the effectiveness of a preparation. Equally, evidence for a medicine does not tell you whether a particular service will fit your communication needs.
Full analysis — 4 more sectionsPricing changed; check the current quote · What the evidence does and does not establish · Ask which pharmacy is involved now · Who should compare Mochi
Pricing changed; check the current quote
Mochi’s update, revised in September 2026, describes dose-dependent medication pricing. It gives representative semaglutide prices of $60–$99 and tirzepatide prices of $90–$199 per month, with variation by prescription, state and pharmacy. Membership remains separate. This supersedes the assumption that every dose carries one identical medication price. 4
The sensible budget question is the complete amount due for the plan being offered now, plus what could change later. Do not choose a dose to fit an advertisement. Tell the clinician about affordability so that cost can be considered alongside clinical suitability, without independently changing treatment.
What the evidence does and does not establish
STEP 1 is relevant to semaglutide’s weight-management evidence. It does not evaluate Mochi membership or establish equivalence for every compounded formulation. The study and the provider’s service should therefore be assessed separately. A care subscription is not a clinical trial, and the ingredient’s evidence does not certify a pharmacy’s finished product. 2
FDA’s guidance explains that compounded GLP-1 preparations are not FDA-approved products. Ask why the particular proposed formulation is appropriate rather than treating the lower price as the entire rationale. 3
Ask which pharmacy is involved now
Mochi’s current weight-loss page describes pharmacy choice. Its older compounding discussion refers to 503A pharmacies. Those disclosures make the pharmacy an important part of the decision, rather than an invisible logistics detail. Get the selected pharmacy’s name and contact information before fulfillment. 67
Mochi also maintains a page about Aequita quality reports. That page says work with the pharmacy would not resume until the stated regulatory conditions were satisfied. This review does not establish whether those conditions have since been met or whether that pharmacy will fill your order. A historical report is not proof of a current supply relationship. 5
When a report is supplied, check that it concerns the relevant formulation and lot. Ask what the report measures, who performed the testing and whether another document is needed to answer your question. The existence of a report and the applicability of that report are different matters.
Who should compare Mochi
Mochi is a useful candidate for a patient who values ongoing care and wants to compare pharmacy-dependent options. Someone looking for a single permanent all-in price should obtain explicit written terms before relying on an advertisement. The practical goal is a clear care arrangement and a prescription whose rationale you understand, rather than the lowest isolated advertised price.
Questions
Frequently asked questions
Is the starting medication price all-inclusive?
No. Mochi states that membership is separate from medication. Confirm the current combined charge for your selected plan.
Does every semaglutide dose cost the same?
The September 2026 update describes dose-dependent medication pricing, with state and pharmacy variation. The account-specific order price matters.
Does an Aequita report confirm my current pharmacy?
No. A historical report page does not identify the pharmacy assigned to a new prescription. Confirm that directly with the care team.
Compare
Others selling what Mochi Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Mochi Health is on
Method
How we checked this
Non-product facts last checked October 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Mochi Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 7 sources
- Mochi Health (2026). Current public treatment offer. Mochi Health; accessed October 13, 2026. the Mochi Health site
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH et al.; accessed October 13, 2026. https://pubmed.ncbi.nlm.nih.gov/33567185/
- FDA (2026). Concerns with unapproved GLP-1 drugs. FDA; accessed October 13, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Mochi Health (2026). Per-dose pricing: what changed. Mochi Health; accessed October 13, 2026. the Mochi Health site
- Mochi Health (2026). Aequita pharmacy quality reports. Mochi Health; accessed October 13, 2026. the Mochi Health site
- Mochi Health (2026). Weight-loss care. Mochi Health; accessed October 13, 2026. the Mochi Health site
- Mochi Health (2026). Mounjaro and compounded pharmacy discussion. Mochi Health; accessed October 13, 2026. the Mochi Health site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.